Zenlabs Ethica Limited (BOM:530697)

Market Cap	199.27M
Revenue (ttm)	505.37M
Net Income (ttm)	2.61M
Shares Out	6.51M
EPS (ttm)	0.40
PE Ratio	76.19
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	257
Average Volume	1,477
Open	31.98
Previous Close	31.46
Day's Range	30.56 - 31.98
52-Week Range	27.33 - 52.10
Beta	-0.79
RSI	41.12
Earnings Date	Aug 7, 2025

About Zenlabs Ethica

Zenlabs Ethica Limited engages in the marketing and distribution of pharmaceutical products in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 1993
• Employees: 65
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530697

Financial Performance

In 2024, Zenlabs Ethica's revenue was 514.23 million, a decrease of -12.19% compared to the previous year's 585.63 million. Earnings were 2.69 million, a decrease of -36.09%.